The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: Effects on menopause symptoms and bone markers

Maturitas

Volumn 44, Issue SUPPL., 2003, Pages

  Wuttke, W ^a   Seidlova Wuttke D ^a   Gorkow, C ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Bionorica AG   (Germany)

Author keywords

Bone metabolism; Cimicifuga racemosa; Menopausal complaints; Phytoestrogens; SERM

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CIMICIFUGA RACEMOSA EXTRACT; CONJUGATED ESTROGEN; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTICLE; BONE DEFECT; BONE METABOLISM; CIMICIFUGA RACEMOSA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SYNTHESIS; ENDOMETRIUM; ENZYME ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICINAL PLANT; MENOPAUSAL SYNDROME; MULTICENTER STUDY; OSSIFICATION; RANDOMIZED CONTROLLED TRIAL; SCALE UP; THICKNESS; TRANSVAGINAL ECHOGRAPHY; VAGINA CYTOLOGY;

CIMICIFUGA; CIMICIFUGA RACEMOSA;

EID: 0037436823     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(02)00350-X     Document Type: Article

References (33)

1. Liehr J.G. Genotoxicity of the steroidal oestrogens oestron and oestradiol: possible mechanism of uterine and mammary cancer development. Hum. Reprod. Update. 7:2001;273-281.
2. Colditz G.A., Hankinson S.E., Hunter D.J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 332:1995;1589-1593.
3. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the women's health initiative randomized controlled trial. J. Am. Med. Assoc. 288:2002;321-333.
4. Southcott B.M. Carcinoma of the endometrium. Drugs. 61:2001;1395-1405.
5. Feeley K.M., Wells M. Hormone replacement therapy and the endometrium. J. Clin. Pathol. 54:2001;435-440.
6. Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., Stampfer M.J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 133:2000;933-941.
7. Mikkola T.S., Clarkson T.B. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc. Res. 53:2002;605-619.
8. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group, J. Am. Med. Assoc. 1998;280:605-13.
9. Herrington D.M., Potvin Klein K. Cardiovascular trials of estrogen replacement therapy. Ann. NY Acad. Sci. 949:2001;153-162.
10. Ariyo A.A., Villablanca A.C. Estrogens and lipids: can HRT designer estrogens, and phytoestrogens reduce cardiovascular risk markers after menopause? Postgrad. Med. 111:2002;23-30.
11. Clarkson T.B. Soy, soy phytoestrogens and cardiovascular disease. J. Nutr. 132:2002;566S-569S.
12. Bjarnason N.H., Hassager C., Christiansen C. Postmenopausal bone remodelling and hormone replacement. Climacteric. 1:1998;72-79.
13. Santen R.J., Pinkerton J.V., Conaway M., Ropka M., Wisniewski L., Demers L., Klein K.O. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause. 9:2002;179-187.
14. Einer-Jensen N., Zhao J., Andersen K.P., Kristoffersen K. Cimicifuga and Melbrosia lack oestrogenic effects in mice and rats. Maturitas. 25:1996;149-153.
15. Seidlová-Wuttke D, Jarry H, Viereck V, Heiden I, Christoffel V, Spengler B, Wuttke W. Cimicifuga racemosa: a selective estrogen receptor modulator? In: Samsioe G, Skouby S, editors. Midlife Health - Current Concepts and Challenges for the Future. Amsterdam: Elsevier, 2001.
16. Liske E., Hänggi W., Henneicke-vonZepelin H.H., Boblitz N., Wüstenberg P., Rahlfs V.W. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J. Womens Health Gend. Based Med. 11:2002;163-174.
17. Gajdos C., Jordan V.C. Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade. Clin. Breast Cancer. 2:2002;272-281.
18. Anderson P.W., Cox D.A., Sashegyi A., Paul S., Silfen S.L., Walsh B.W. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. Maturitas. 25:2001;71-77.
19. Note for guidance on good clinical practice, CPMP/ICH/135/95. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), London: Committee for Proprietary Medicinal Product (CPMP), 1997.
20. World Medical Association Declaration of Helsinki. Ethical principles for Medical Research Involving Human Subjects, last amended by the 48th World Medical Assembly, Somerset West, Republic of South Africa, 1996.
21. Dallal G.E. Design-Power Analysis and Expected Mean Squares. A Supplementary Module for SYSTAT and SYGRAPH. 1988;Systat, Inc, Evanston, IL.
22. Hauser G.A., Huber I.C., Keller P.J., Lauritzen C., Schneider H.P.G. Evaluation der klimakterischen beschwerden (menopause rating scale (MRS)) zentralblatt für gynäkologie. 116:1994;16-23.
23. Schneider H.P.G., Rosemeier H.P., Schnitker J., Gerbsch S., Turck R. Application and factor analysis of the menopause rating scale (MRS) in a post-marketing surveillance study of Climen. Maturitas. 37:2000;113-124.
24. Kuhl H., Taubert H.-D. Das Klimakterium, Pathophysiologie-Klinik-Therapie. 1987;178-181 Georg Thieme, Stuttgart, NY.
25. Stoll W. Phytotherapeutikum beeinflusst atrophisches vaginalepithel: doppelblindversuch Cimicifuga vs Östrogenpräparat (phytopharmacon influences atrophic vaginal epithelium: double-blind study - Cimicifuga vs. estrogenic substances). Therapeuticum. 1:1987;23-31.
26. Tataryn I.V., Lomax P., Bajorek J.G., et al. Postmenopausal hot flushes: a disorder of thermoregulation. Maturitas. 2:1980;101-107.
27. Jarry H., Perschl A., Wuttke W. Further evidence that preoptic anterior hypothalamic GABAergic neurons are part of the GnRH pulse and surge generator. Acta Endocrinol. 118:1988;573-579.
28. Shughrue P.J., Lane M.V., Merchenthaler I. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J. Comp. Neurol. 388:1997;507-525.
29. Shughrue P.J., Merchenthaler I. Distribution of estrogen receptor beta immunoreactivity in the rat central nervous system. J. Comp. Neurol. 436:2001;64-81.
30. Bord S., Horner A., Beavan S., Compston J. Estrogen receptors alpha and beta are differentially expressed in developing human bone. J. Clin. Endocrinol. Metab. 86:2001;2309-2314.
31. Okazaki R., Inoue D., Shibata M., et al. Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology. 143:2002;2349-2356.
32. Braidman I.P., Hainey L., Batra G., Selby P.L., Saunders P.T., Hoyland J.A. Localization of estrogen receptor beta protein expression in adult human bone. J. Bone Miner. Res. 16:2001;214-220.
33. Westerlind K.C., Wronski T.J., Ritman E.L., et al. Estrogen regulates the rate of bone turnover but bone balance in ovariectomized rats is modulated by prevailing mechanical strain. Proc. Natl. Acad. Sci. USA. 94:1997;4199-4204.